Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure–activity relationships, and ADMET liabilities
Wei Zhao, Beibei Bie, Juning Wang, Xueying Liu, Huanle Fang, Rui Niu · 2026
Read Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure–activity relationships, and ADMET liabilities by Wei Zhao, Beibei Bie, Juning Wang, Xueying Liu, Huanle Fang, Rui Niu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13385078.txt.
Description
Wei Zhao and co-authors organize cancer drug design around the pyridine ring in a 2026 medicinal chemistry review. Pyridine appears in many approved cancer drugs, yet its value depends heavily on context, the authors stress. Sections sort compounds by what the ring actually does, from target binding to property tuning.
Examples span classic drugs, antibody-drug conjugate payloads, targeted degraders, and metal complexes with several pyridine units. Each case is weighed for structure-activity patterns and for body handling and safety liabilities. The closing message treats pyridine as a design module to validate case by case, not a magic scaffold.
Catalog record
| CREATOR | Wei Zhao, Beibei Bie, Juning Wang, Xueying Liu, Huanle Fang, Rui Niu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40880 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |